[Skip to Navigation]
Comment & Response
June 2015

Analyses Comparing Visual Acuity Between Ranibizumab and Bevacizumab in the Comparison of Age-Related Macular Degeneration Treatments Trials

Author Affiliations
  • 1Department of Ophthalmology, Scheie Eye Institute, Perelman School of Medicine, University of Pennsylvania, Philadelphia
JAMA Ophthalmol. 2015;133(6):726. doi:10.1001/jamaophthalmol.2015.0502

To the Editor We thank Dr Messori1 for the interest in our 2 articles from the Comparison of Age-Related Macular Degeneration Treatments Trials.2,3 Dr Messori believes that results in the 2 articles for comparison of visual acuity between eyes treated with bevacizumab and eyes treated with ranibizumab are contradictory.1 Dr Messori speculates that analyzing visual acuity change from baseline as a dichotomous variable (sustained loss of ≥15 letters) in the article on sustained visual acuity loss3 but as a continuous variable (mean change in visual acuity from baseline) in the article on the 2-year main results2 may be responsible for the apparent contradiction. We believe there is no contradiction because the objectives of the 2 articles were different and because different approaches to data analysis were warranted.

Add or change institution